---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023810"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-05-15T20:20:37+00:00"
generated_at: "2026-05-15T21:11:32.233827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway

## Summary
- Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.
- Cash and equivalents $0.7M at March 31, 2026; subsequent $2.0M convertible preferred financing closed April 7.
- Achieved 50% of interim enrollment target in pivotal PF614-301 Phase 3 trial for moderate to severe pain.
- IRB approval secured for Part 3 of PF614-MPAR-102; first peer-reviewed MPAR data published in Journal of Opioid Management.
- Board initiated formal review of strategic alternatives, including partnerships and licensing opportunities.

## SEC filing metadata
- accession: 0001493152-26-023810
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-05-15T20:20:37+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/0001493152-26-023810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023810
- JSON: https://secwatch.observer/filing/0001493152-26-023810.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023810.txt

## Key facts
- Earnings Releases
  Ensysce Biosciences, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 15, 2026, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226023810/0001493152-26-023810-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.